JP Morgan Maintains Overweight on Replimune Group, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Replimune Group (NASDAQ:REPL) but lowers the price target from $17 to $14.

August 13, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on Replimune Group but lowers the price target from $17 to $14.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100